供给侧改革下的医药产业创新政策环境研究——基于美国经验

摘要

政府、药企、科研机构、高校等创新主体是医药产业创新体系中最重要的要素.我国医药产业创新发展水平整体较低,主要原因之一是政府未能发挥在创新体系中对其他创新主体的引导和激励作用.本文以美国医药创新体系为研究对象,系统梳理了美国医药产业创新发展路径,明确政策环境在各阶段所发挥的作用;在此基础上,分析美国医药创新发展过程中的关键产业政策及其基本作用.最终结合我国国情,借助“创新生态系统”基本理论,构建我国医药产业创新发展政策环境,推动形成科学、稳定、可持续发展的创新药物生态系统.%The innovation subjects,such as governments,pharmaceutical companies,research institutes and universities,are the most fundamental elements in the innovation system of pharmaceutical industry.The primary cause of low level innovation of pharmaceutical industry is that the government fails to play an active role of guidance and incentives in the innovation system.In this pater,the American innovation system of pharmaceutical industry,which the innovative development path is analyzed,was taken as the object of study,to figure out the work of it on promoting innovation.On this basis,the key industry policy and its function in the innovative development of American pharmaceutical industry was studied.Ultimately,combined with our national conditions,it was suggested that innovation ecosystem be taken as the theoretical reference to establish the policy environment for innovative development of pharmaceutical industry and then to promote the formation of scientific,stable and sustainable pharmaceutical innovation ecosystem.